Company intelligence / Profile preview
Imcyse
Liège, Belgiumimcyse.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 2
01
Overview
Completed Phase 1 trial in type 1 diabetes with promising results; Phase 2 study in type 1 diabetes fully enrolled with top-line data expected in 2024; Phase 1/2 clinical trial in Multiple Sclerosis initiated in April 2022
- Therapeutic areas
- EndocrinologyNeurologyImmunology
- Modalities
- Synthetic peptides (Imotopes™)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Pfizer (Rheumatoid Arthritis program)CLAIMS (European Health Initiative Project)
Beyond the preview
Go deeper on Imcyse.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Imcyse.